The Venture Capital Podcast with Fexingo · 2026-07-15 · 7 min
In this episode, Lucas and Luna dive into the trend of venture capitalists betting big on AI-powered drug discovery, anchored by the news that an OpenAI researcher is launching a startup valued at $2 billion. They explore why AI-first biotech is attracting massive funding, how it differs from traditional pharma R&D, and what the risks are. Plus, they touch on market signals like the ARKG genomics ETF's recent dip and the broader tech rally led by Meta and NVIDIA. A focused conversation on the intersection of artificial intelligence and biology. #AIDrugDiscovery #VentureCapital #Biotech #OpenAI #MilesWang #DrugDevelopment #PharmaAI #Genomics #ARKG #StartupValuation #VCRisk #BusinessPodcast #Technology #FexingoBusiness #BusinessPodcast #Podcast #2026 #AIStartups Keep every episode free: buymeacoffee.com/fexingo
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Synthetic User Startups Are Venture Capital's New Frontier44 / 100Why VCs Are Betting on Private Space Pilots for the US Space Force76 / 100Why VCs Are Backing Niche AI Copilots for Every Industry72 / 100The Bending Spoons IPO and Why VCs Love Bootstrapped Startups60 / 100Why VCs Are Betting on Together AI's 800 Million Round74 / 100
